HMOX1 and colorectal carcinoma: We determined that treatment with cetuximab significantly enhanced the cytotoxicity of RSL3 in KRAS-mutated CRC cells and promoted RSL3-induced ferroptosis by suppressing Nrf2/HO-1 expression.